India markets close in 1 hour 42 minutes
  • BSE SENSEX

    47,989.65
    -91.02 (-0.19%)
     
  • Nifty 50

    14,376.30
    -29.85 (-0.21%)
     
  • USD/INR

    75.0125
    -0.0975 (-0.13%)
     
  • Dow

    33,815.90
    -321.41 (-0.94%)
     
  • Nasdaq

    13,818.41
    -131.81 (-0.94%)
     
  • BTC-INR

    3,621,578.50
    -442,435.75 (-10.89%)
     
  • CMC Crypto 200

    1,099.12
    -143.93 (-11.58%)
     
  • Hang Seng

    29,054.79
    +299.45 (+1.04%)
     
  • Nikkei

    29,020.63
    -167.54 (-0.57%)
     
  • EUR/INR

    90.4320
    +0.1574 (+0.17%)
     
  • GBP/INR

    104.1023
    +0.1655 (+0.16%)
     
  • AED/INR

    20.3540
    -0.0510 (-0.25%)
     
  • INR/JPY

    1.4351
    +0.0005 (+0.03%)
     
  • SGD/INR

    56.5280
    -0.0040 (-0.01%)
     

Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021

Bio-Path Holdings, Inc.
·1-min read

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, March 10, 2021 at 8:30 a.m. ET to report financial results for the year ended December 31, 2020 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 6296959. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies. For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369